Clinical trials: Neoplasms, Pharyngeal
Nasopharyngeal Carcinoma
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with S-1 CCRT for locally advanced NPC.
- Trial name
- NCT03668366
- Testing
- S-1
- Where
- China
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Fudan University
Nasopharyngeal Cancer
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01074021
- Testing
- Nimotuzumab
- Where
- 24 sites in China
- Volunteers
- 480 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients
Primary objective: Evaluate and compare incidence of acute and long-term taste dysfunction in chemoradiation plus dental stent group vs.
- Trial name
- NCT06733948
- Testing
- Dental stent, No dental stent
- Where
- 2 sites in Singapore
- Volunteers
- 50 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
GNT Induction Treatment in Locally Advanced NPC
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal…
- Trial name
- NCT06026878
- Testing
- gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Air Force Military Medical University, China
Nasopharyngeal Carcinoma
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group.
- Trial name
- NCT05587543
- Testing
- PK Blood Collection, CAR, TCR
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Chronic Inflammation of Hypopharynx, Hoarseness
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
The aim of the project is to compare NBI endoscopy and standard endoscopic method using white light and evaluate accuracy both methods in early detection and diagnosis hypopharyngeal and laryngeal precancerous and cancerous…
- Conditions
- Chronic Inflammation of Hypopharynx, Hoarseness, Macroscopic Laryngeal Lesions, Histological Confirmation of Dysplasia
- Trial name
- NCT02217358
- Testing
- NBI endoscopy
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of…
- Trial name
- NCT04974398
- Testing
- Penpulimab
- Where
- 56 sites in United States, Australia and 3 more
- Volunteers
- 296 people
- Sponsor
- Akeso
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Dysphagia, Head and Neck Cancer
Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically
Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful swallowing, swallowing difficulty (dysphagia), and…
- Trial name
- ESSI-SURG (NCT06192771)
- Testing
- ESSI-SURG, Standard-of-Care
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Local Advanced High Risk Nasopharyngeal Carcinoma
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial
This is an randomized controlled, multicenter clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in…
- Trial name
- NCT02143388
- Testing
- IMRT combine with cisplatin concurrent chemotherapy, IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhao Chong
Nasopharyngeal Carcinoma
Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to compare the toxicity and therapeutic efficacy of proton or photon combined with carbon ion radiotherapy for newly diagnosed nasopharyngeal carcinoma.Participants will be randomized to 2 arms.
- Trial name
- NCT04528394
- Testing
- Photon, Proton, Carbon ion
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Head Neck Cancer, Oral Cancer
Swallowing Function in Patients With Head and Neck Cancers
Head and neck cancer (HNC) is the sixth most common cancer worldwide, accounting for 2.8% of all malignancies. The presence of tumor itself, as well as the treatment, can result in neuromuscular damage affecting any stage of the…
- Trial name
- NCT05833841
- Testing
- Surface Electromyography and Video fluoroscopy
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Banaras Hindu University
Nasopharyngeal Carcinoma (NPC)
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
This study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- RAIRI-NPC (NCT07590024)
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 651 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dysphagia
Consequences of an Initial Treatment for Head and Neck Cancer on Swallowing Function: Impact on Nutritional Status
The aim of the present prospective study was to assess dysphagia (occurrence, severity, length) in head and neck cancer (HNC), from diagnosis to 18 months after their first line treatment regardless of the treatment.
- Trial name
- DYSPHAGIA (NCT03068559)
- Volunteers
- 240 people
- Sponsor
- Centre Antoine Lacassagne
Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase II Trial of Allovectin-7® for Head and Neck Cancer
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck
- Trial name
- NCT00050388
- Testing
- Allovectin-7®
- Where
- 10 sites in United States
- Sponsor
- Vical
Oropharynx Cancer, Squamous Cell Carcinoma of the Oral Cavity
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer.
- Trial name
- NCT01108042
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 4 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Orlando Guntinas-Lichius, Prof. Dr. med.
Cancer of the Head and Neck, Oropharynx Cancer
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the…
- Conditions
- Cancer of the Head and Neck, Oropharynx Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Throat Carcinoma
- Trial name
- ENID (NCT04444869)
- Testing
- Cisplatin injection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Missouri-Columbia
Radiotherapy, Nasopharyngeal Carcinoma
Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study
Cerebral radiation necrosis (CRN) is a well-documented late complication of radiation therapy for cancers, and may have a devastating effect on the patient's quality of life (QOL).
- Conditions
- Radiotherapy, Nasopharyngeal Carcinoma, Cerebral Radiation Necrosis, MRI
- Trial name
- NCT01884987
- Testing
- GM1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Larynx Cancer, Hypopharynx Cancer
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
Larynx preservation remains a very challenging approach in patients with larynx/pharynx cancer. A first attempt consisted of induction chemotherapy followed in good responders by irradiation.
- Trial name
- NCT00169247
- Testing
- cetuximab, Cisplatin, Radiotherapy 70 Gy, 35 fractions
- Where
- 3 sites in France
- Volunteers
- 156 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Nasopharyngeal Neoplasms
Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma
Although patient-reported adverse events have been promoted as an essential element in clinical trials and daily managements, their efficacy remained unknown.
- Trial name
- NCT03093649
- Testing
- adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire, do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.